Publications by authors named "Jan Murin"

Claim this Profile
N
Non-persistence with multiple secondary prevention medications for peripheral arterial disease among older hypertensive patients.
Martin Wawruch, Miriam Petrova, Denisa Celovska, Sofa D Alfian, Tomas Tesar, Jan Murin

Front Pharmacol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with non-adherence to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in older patients with peripheral arterial disease.
Martin Wawruch, Miriam Petrova, Tomas Tesar, Jan Murin, Patricia Schnorrerova

Front Pharmacol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obesity, elevated levels of fasting plasma glucose and type 2 diabetes are associated with aortic stiffness.
Viera Kupcova, Jan Murin, Sona Wimmerova, Maria Potocarova, Ladislav Turecky

Bratisl Lek Listy· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reinitiation and Subsequent Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers among New and Prevalent Users Aged 65 Years or More with Peripheral Arterial Disease.
Martin Wawruch, Jan Murin, Tomas Tesar, Miriam Petrova, Martina Paduchova

Biomedicines· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gender Differences in Non-Persistence with Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers among Older Hypertensive Patients with Peripheral Arterial Disease.
Martin Wawruch, Jan Murin, Tomas Tesar, Martina Paduchova, Miriam Petrova

Biomedicines· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adherence to Antiplatelet Medications among Persistent and Non-Persistent Older Patients with Peripheral Arterial Disease.
Martin Wawruch, Jan Murin, Tomas Tesar, Martina Paduchova, Miriam Petrova

Biomedicines· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reinitiation and Subsequent Discontinuation of Antiplatelet Treatment in Nonpersistent Older Patients with Peripheral Arterial Disease.
Martin Wawruch, Jan Murin, Tomas Tesar, Martina Paduchova, Miriam Petrova

Biomedicines· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-Persistence With Antiplatelet Medications Among Older Patients With Peripheral Arterial Disease.
Martin Wawruch, Jan Murin, Tomas Tesar, Martina Paduchova, Miriam Petrova

Front Pharmacol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Secondary prevention after acute coronary syndrome].
Ján Murín, Jozef Bulas, Udovít Gašpar, Alexander Klabník, Martin Wawruch

Vnitr Lek· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-Adherence to Statin Treatment in Older Patients with Peripheral Arterial Disease Depending on Persistence Status.
Martin Wawruch, Gejza Wimmer, Jan Murin, Martina Paduchova, Miriam Petrova

Biomedicines· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors Associated with Reinitiation of Statin Treatment in Older Patients with Peripheral Arterial Disease.
Martin Wawruch, Gejza Wimmer, Jan Murin, Martina Paduchova, Tomas Tesar

Drugs Aging· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world.
Chris J Kapelios, Mitja Lainscak, Gianluigi Savarese, Cécile Laroche, Petar Seferovic, Jan Murin

Eur J Heart Fail· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
Marat Fudim, Jennifer White, Neha J Pagidipati, Yuliya Lokhnygina, Julio Wainstein, Jan Murin

Circulation· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Associated Characteristics Influencing the Risk for Non-Persistence with Statins in Older Patients with Peripheral Arterial Disease.
Martin Wawruch, Gejza Wimmer, Jan Murin, Martina Paduchova, Tomas Tesar

Drugs Aging· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Kausik K Ray, Helen M Colhoun, Michael Szarek, Marie Baccara-Dinet, Deepak L Bhatt, Jan Murin

Lancet Diabetes Endocrinol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[What has the GLAGOV clinical study shown?].
Ján Murín

Vnitr Lek· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Clinical study FOURIER].
Ján Murín

Vnitr Lek· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-persistence with antiplatelet therapy in elderly patients after a transient ischemic attack.
Martin Wawruch, Dusan Zatko, Gejza Wimmer, Jan Luha, Sona Wimmerova, Jan Murin

Aging Clin Exp Res· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age-Related Differences in Non-Persistence with Statin Treatment in Patients after a Transient Ischaemic Attack.
Martin Wawruch, Dusan Zatko, Gejza Wimmer, Jan Luha, Sona Wimmerova, Jan Murin

Clin Drug Investig· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Treatment of dyslipidemia - is here still place for CETP-inhibitors?].
Ján Murín, Miroslav Pernický, Soňa Kiňová

Vnitr Lek· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
Paul M Ridker, James Revkin, Pierre Amarenco, Robert Brunell, Madelyn Curto, Jan Murin

N Engl J Med· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-related characteristics associated with non-persistence with statin therapy in elderly patients following an ischemic stroke.
Martin Wawruch, Dusan Zatko, Gejza Wimmer, Jan Luha, Vasil Hricak, Jan Murin

Pharmacoepidemiol Drug Saf· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central Systolic Hypertension in Patients with Well-Controlled Hypertension.
Jozef Bulas, Mária Potočárová, Ján Murín, Katarína Kozlíková, Ján Luha

Biomed Res Int· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Are some antidiabetic drugs also drugs useful for heart failure treatment?].
Ján Murín

Vnitr Lek· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Is iron important in heart failure?].
Ján Murín, Miroslav Pernický

Vnitr Lek· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis